19 months into Phase 3, MSK collaboration and Peregrine expands trials. Sounds like another 6 months to me before the tipping point begins- second look in. Let's hope the positive tone during the recent CC tells the real story.
In the interim, I plan on picking up additional shares.
Has any other Biotech company in the history of cancer treatment gotten this far along in a Phase 3 trial without a partnership?
News 
Market Data 
Discover 
